Evaluation and treatment of severe and prolonged thrombocytopenia in neonates

Clinics in Perinatology

Volumn 31, Issue 1, 2004, Pages 1-14

  Sola, Martha C ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; RECOMBINANT INTERLEUKIN 2; RECOMBINANT THROMBOPOIETIN;

BONE MARROW CELL; BONE MARROW SUPPRESSION; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE SEVERITY; EVALUATION; EVIDENCE BASED MEDICINE; HLA SYSTEM; HUMAN; LABORATORY TEST; MEDICAL EXAMINATION; NECROTIZING ENTEROCOLITIS; NEWBORN; NEWBORN PERIOD; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; TREATMENT PLANNING;

EID: 2942555265     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clp.2004.03.014     Document Type: Review

References (86)

1. George D, Bussel JB. Neonatal thrombocytopenia. Semin Thromb Hemost 1995;21:276-93.
2. Andrew M, Kelton J. Neonatal thrombocytopenia. Clin Perinatol 1984;11:359-91.
3. Roberts IA, Murray NA. Neonatal thrombocytopenia: new insights into pathogenesis and implications for clinical management. Curr Opin Pediatr 2001;13:16-21.
4. Roberts IA, Murray NA. Thrombocytopenia in the newborn. Curr Opin Pediatr 2003;15:17-23.
5. Roberts I, Murray NA. Neonatal thrombocytopenia: causes and management. Arch Dis Child Fetal Neonatal Ed 2003;88:F359-64.
6. Sola MC, Del Vecchio A, Rimsza LM. Evaluation and treatment of thrombocytopenia in the neonatal intensive care unit. Clin Perinatol 2000;27:655-79.
7. Murray NA, Roberts IA. Circulating megakaryocytes and their progenitors in early thrombocytopenia in preterm neonates. Pediatr Res 1996;40:112-9.
8. Murray NA, Watts TL, Roberts IA. Endogenous thrombopoietin levels and effect of recombinant human thrombopoietin on megakaryocyte precursors in term and preterm babies. Pediatr Res 1998;43:148-51.
9. Watts TL, Murray NA, Roberts IA. Thrombopoietin has a primary role in the regulation of platelet production in preterm babies. Pediatr Res 1999;46:28-32.
10. Hohlfeld P, Forestier F, Kaplan C, Tissot JD, Daffos F. Fetal thrombocytopenia: a retrospective survey of 5,194 fetal blood samplings. Blood 1994;84:1851-6.
11. Hord JD, Gay JC, Whitlock JA. Thrombocytopenia in neonates with trisomy 21. Arch Pediatr Adolesc Med 1995;149:824-5.
12. Drachman JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 2004;103:390-8.
13. Kato T, Kosaka K, Kimura M, Imamura S, Yamada O, Iwai K, et al. Thrombocytopenia in patients with 22q11.2 deletion syndrome and its association with glycoprotein Ib-beta. Genet Med 2003;5:113-9.
14. Lawrence S, McDonald-McGinn DM, Zackai E, Sullivan KE. Thrombocytopenia in patients with chromosome 22q11.2 deletion syndrome. J Pediatr 2003;143:277-8.
15. Hedberg VA, Lipton JM. Thrombocytopenia with absent radii: a review of 100 cases. Am J Pediatr Hematol Oncol 1988;10:51-64.
16. Gershanik JJ, Morgan SK, Akers R. Fanconi's anemia in a neonate. Acta Paediatr Scand 1972;61:623-5.
17. O'Neill EM VS. Neonatal aplastic anemia and Fanconi's anemia. Arch Dis Child 1963;38:92.
18. Thompson AA, Woodruff K, Feig SA, Nguyen LT, Schanen NC. Congenital thrombocytopenia and radio-ulnar synostosis: a new familial syndrome. Br J Haematol 2001;113:866-70.
19. Thompson AA, Nguyen LT. Amegakaryocytic thrombocytopenia and radio-ulnar synostosis are associated with HOXA11 mutation. Nat Genet 2000;26:397-8.
20. Tomer A, Hanson SR, Harker LA. Autologous platelet kinetics in patients with severe thrombocytopenia: discrimination between disorders of production and destruction. J Lab Clin Med 1991;118:546-54.
21. Castle V, Coates G, Mitchell LG, O'Brodovich H, Andrew M. The effect of hypoxia on platelet survival and site of sequestration in the newborn rabbit. Thromb Haemost 1988;59:45-8.
22. Harker LA, Finch CA. Thrombokinetics in man. J Clin Invest 1969;48:963-74.
23. Cole JL, Marzec UM, Gunthel CJ, Karpatkin S, Worford L, Sundell IB, et al. Ineffective platelet production in thrombocytopenic human immunodeficiency virus-infected patients. Blood 1998;91:3239-46.
24. Sola MC, Rimsza LM. Mechanisms underlying thrombocytopenia in the neonatal intensive care unit. Acta Paediatr Suppl 2002;91:66-73.
25. Castle V, Andrew M, Kelton J, Giron D, Johnston M, Carter C. Frequency and mechanism of neonatal thrombocytopenia. J Pediatr 1986;108:749-55.
26. Silliman CC, Cusack NA, Swanson NJ, Ghaffarifar S, Ambruso DR. Platelets and neutrophils from healthy term neonates exhibit increased levels of immunoglobulins. Pediatr Res 1995;38:993-7.
27. Emmons RV, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996;87:4068-71.
28. Sola MC, Calhoun DA, Hutson AD, Christensen RD. Plasma thrombopoietin concentrations in thrombocytopenic and non-thrombocytopenic patients in a neonatal intensive care unit. Br J Haematol 1999;104:90-2.
29. Sola MC, Juul SE, Meng YG, Garg S, Sims P, Calhoun DA, et al. Thrombopoietin (Tpo) in the fetus and neonate: Tpo concentrations in preterm and term neonates, and organ distribution of Tpo and its receptor (c-mpl) during human fetal development. Early Hum Dev 1999;53:239-50.
30. Tsukahara A, Sato Y, Yamamoto S, Suzuki S, Nakatsuka H, Watanabe T, et al. Thrombopoietin levels and peripheral platelet counts following living related donor liver transplantation. Hepatogastroenterology 2003;50:227-30.
31. Mehta AB, Burroughs AK. Thrombopoietin concentration after orthotopic liver transplantation. Br J Haematol 2001;114:960-1.
32. Wolber EM, Ganschow R, Burdelski M, Jelkmann W. Hepatic thrombopoietin mRNA levels in acute and chronic liver failure of childhood. Hepatology 1999;29:1739-42.
33. Peck-Radosavljevic M, Wichlas M, Zacherl J, Stiegler G, Stohlawetz P, Fuchsjager M, et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000;95:795-801.
34. Kienast J, Schmitz G. Flow cytometric analysis of thiazole orange uptake by platelets: a diagnostic aid in the evaluation of thrombocytopenic disorders. Blood 1990;75:116-21.
35. Joseph MA, Adams D, Maragos J, Saving KL. Flow cytometry of neonatal platelet RNA. J Pediatr Hematol Oncol 1996;18:277-81.
36. Peterec SM, Brennan SA, Rinder HM, Wnek JL, Beardsley DS. Reticulated platelet values in normal and thrombocytopenic neonates. J Pediatr 1996;129:269-74.
37. Saxonhouse MA SM, Ignatz ME, Pastos KM, Hutson AD, Christensen RD, Rimsza LM. Reticulated platelet percentage and mean platelet volume changes in preterm neonates (a) [abstract]. Pediatr Res 2003;53:282A.
38. Robinson M, Machin S, Mackie I, Harrison P. Comparison of glycocalicin, thrombopoietin and reticulated platelet measurement as markers of platelet turnover in HIV+ samples. Platelets 2001;12:108-13.
39. van den Oudenrijn S, Bruin M, Folman CC, Bussel J, de Haas M, von dem Borne AE. Three parameters, plasma thrombopoietin levels, plasma glycocalicin levels and megakaryocyte culture, distinguish between different causes of congenital thrombocytopenia. Br J Haematol 2002;117:390-8.
40. Fabris F, Cordiano I, Steffan A, Ramon R, Scandellari R, Nichol JL, et al. Indirect study of thrombopoiesis (TPO, reticulated platelets, glycocalicin) in patients with hereditary macrothrombocytopenia. Eur J Haematol 2000;64:151-6.
41. Patrick CH, Lazarchick J. The effect of bacteremia on automated platelet measurements in neonates. Am J Clin Pathol 1990;93:391-4.
42. O'Connor TA, Ringer KM, Gaddis ML. Mean platelet volume during coagulase-negative staphylococcal sepsis in neonates. Am J Clin Pathol 1993;99:69-71.
43. Guida JD, Kunig AM, Leef KH, McKenzie SE, Paul DA. Platelet count and sepsis in very low birth weight neonates: is there an organism-specific response? Pediatrics 2003;111:1411-5.
44. Levin J, Bessman JD. The inverse relation between platelet volume and platelet number: abnormalities in hematologic disease and evidence that platelet size does not correlate with platelet age. J Lab Clin Med 1983;101:295-307.
45. Sola MC, Christensen RD, Hutson AD, Tarantal AF. Pharmacokinetics, pharmacodynamics, and safety of administering pegylated recombinant megakaryocyte growth and development factor to newborn rhesus monkeys. Pediatr Res 2000;47:208-14.
46. Koike Y, Yoneyama A, Shirai J, Ishida T, Shoda E, Miyazaki K, et al. Evaluation of thrombopoiesis in thrombocytopenic disorders by simultaneous measurement of reticulated platelets of whole blood and serum thrombopoietin concentrations. Thromb Haemost 1998;79:1106-10.
47. Kurata Y, Hayashi S, Kiyoi T, Kosugi S, Kashiwagi H, Honda S, et al. Diagnostic value of tests for reticulated platelets, plasma glycocalicin, and thrombopoietin levels for discriminating between hyperdestructive and hypoplastic thrombocytopenia. Am J Clin Pathol 2001;115:656-64.
48. Sola MC CR, Pastos K, Walker D, Rimsza LM. Mechanisms underlying severe and prolonged thrombocytopenia in neonates [abstract]. Pediatr Res 2004;55:291A.
49. Sola MC, Rimsza LM, Christensen RD. A bone marrow biopsy technique suitable for use in neonates. Br J Haematol 1999;107:458-60.
50. Del Vecchio A, Sola MC, Theriaque DW, Hutson AD, Kao KJ, Wright D, et al. Platelet transfusions in the neonatal intensive care unit:factors predicting which patients will require multiple transfusions. Transfusion 2001;41:803-8.
51. Garcia MG, Duenas E, Sola MC, Hutson AD, Theriaque D, Christensen RD. Epidemiologic and outcome studies of patients who received platelet transfusions in the neonatal intensive care unit. J Perinatol 2001;21:415- 20.
52. Murray NA. Evaluation and treatment of thrombocytopenia in the neonatal intensive care unit. Acta Paediatr Suppl 2002;91:74-81.
53. Strauss RG, Levy GJ, Sotelo-Avila C, Albanese MA, Hume H, Schloz L, et al. National survey of neonatal transfusion practices: II. Blood component therapy. Pediatrics 1993;91:530-6.
54. Andrew M, Vegh P, Caco C, Kirpalani H, Jefferies A, Ohlsson A, et al. A randomized, controlled trial of platelet transfusions in thrombocytopenic premature infants. J Pediatr 1993;123:285-91.
55. Roberts IA, Murray NA. Management of thrombocytopenia in neonates. Br J Haematol 1999;105:864-70.
56. Blanchette VS, Kuhne T, Hume H, Hellmann J. Platelet transfusion therapy in newborn infants. Transfus Med Rev 1995;9:215-30.
57. Calhoun DA, Christensen RD, Edstrom CS, Juul SE, Ohls RK, Schibler KR, et al. Consistent approaches to procedures and practices in neonatal hematology. Clin Perinatol 2000;27:733-53.
58. Strauss RG. Blood banking and transfusion issues in perinatal medicine. In: Christensen R, editor. Hematologic problems of the neonate. Philadelphia: W.B. Saunders; 2000. p. 405-25.
59. Voak D, Cann R, Finney RD, Fraser ID, Mitchell R, Murphy MF, et al. Guidelines for administration of blood products: transfusion of infants and neonates. British Committee for Standards in Haematology Blood Transfusion Task Force. Transfus Med 1994;4:63-9.
60. Blanchette VS, Hume HA, Levy GJ, Luban NL, Strauss RG. Guidelines for auditing pediatric blood transfusion practices. Am J Dis Child 1991;145:787-96.
61. Haematology BCfSi. Transfusion guidelines for neonates and older children. Br J Haematol 2004;124:433-53.
62. Strauss RG. Data-driven blood banking practices for neonatal RBC transfusions. Transfusion 2000;40:1528-40.
63. Sanders MR, Graeber JE. Posttransfusion graft-versus-host disease in infancy. J Pediatr 1990;117:159-63.
64. Ohto H, Anderson KC. Posttransfusion graft-versus-host disease in Japanese newborns. Transfusion 1996;36:117-23.
65. Blanchette VS. Neonatal alloimmune thrombocytopenia: a clinical perspective. Curr Stud Hematol Blood Transfus 1988;54:112-26.
66. Blanchette VS, Johnson J, Rand M. The management of alloimmune neonatal thrombocytopenia. Baillieres Best Pract Res Clin Haematol 2000;13:365-90.
67. Sidiropoulos D, Straume B. The treatment of neonatal isoimmune thrombocytopenia with intravenous immunoglobin (IgG i.v.). Blut 1984;48:383-6.
68. Massey GV, McWilliams NB, Mueller DG, Napolitano A, Maurer HM. Intravenous immunoglobulin in treatment of neonatal isoimmune thrombocytopenia. J Pediatr 1987;111:133-5.
69. Isaacs C, Robert NJ, Bailey FA, Schuster MW, Overmoyer B, Graham M, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 1997;15:3368-77.
70. Smith Jr JW. Tolerability and side-effect profile of rhIL-11. Oncology (Huntingt) 2000;14(Suppl 8):41-7.
71. Bussel JB, Mukherjee R, Stone AJ. A pilot study of rhuIL-11 treatment of refractory ITP. Am J Hematol 2001;66:172-7.
72. Braithwaite K, Abu-Ghosh A, Anderson L, Cairo MS. Treatment of severe thrombocytopenia with IL-11 in children withWiskott-Aldrich syndrome. J Pediatr Hematol Oncol 2002;24:323-6.
73. Goldman SC, Bracho F, Davenport V, Slack R, Areman E, Shen V, et al. Feasibility study of IL-11 and granulocyte colony-stimulating factor after myelosuppressive chemotherapy to mobilize peripheral blood stem cells from heavily pretreated patients. J Pediatr Hematol Oncol 2001;23:300-5.
74. McCloy MP, Roberts IA, Howarth LJ, Watts TL, Murray NA. Interleukin-11 levels in healthy and thrombocytopenic neonates. Pediatr Res 2002;51:756- 60.
75. Dame C, Cremer M, Ballmaier M, Bartmann P, Bald R, Schild RL, et al. Concentrations of thrombopoietin and interleukin-11 in the umbilical cord blood of patients with fetal alloimmune thrombocytopenia. Am J Perinatol 2001;18:335-44.
76. Dickinson EC, Tuncer R, Nadler EP, Koltuksuz U, Boyle P, Alber SM, et al. Recombinant human interleukin-11 prevents mucosal atrophy and bowel shortening in the defunctionalized intestine. J Pediatr Surg 2000;35:1079- 83.
77. Nadler EP, Stanford A, Zhang XR, Schall LC, Alber SM, Watkins SC, et al. Intestinal cytokine gene expression in infants with acute necrotizing enterocolitis: interleukin-11 mRNA expression inversely correlates with extent of disease. J Pediatr Surg 2001;36:1122-9.
78. Chang M, Williams A, Ishizawa L, Knoppel A, van de Ven C, Cairo MS. Endogenous interleukin-11 (IL-11) expression is increased and prophylactic use of exogenous IL-11 enhances platelet recovery and improves survival during thrombocytopenia associated with experimental group B streptococcal sepsis in neonatal rats. Blood Cells Mol Dis 1996;22:57-67.
79. Kaushansky K, Broudy VC, Lin N, Jorgensen MJ, McCarty J, Fox N, et al. Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci USA 1995;92:3234-8.
80. Sola MC, Du Y, Hutson AD, Christensen RD. Dose-response relationship of megakaryocyte progenitors from the bone marrow of thrombocytopenic and non-thrombocytopenic neonates to recombinant thrombopoietin. Br J Haematol 2000;110:449-53.
81. Sola MC, Dame C, Christensen RD. Toward a rational use of recombinant thrombopoietin in the neonatal intensive care unit. J Pediatr Hematol Oncol 2001;23:179-84.
82. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001;98:3241-8.
83. de Serres M, Ellis B, Dillberger JE, Rudolph SK, Hutchins JT, Boytos CM, et al. Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: evaluation of the potential for thrombopoietin neutralizing antibody production in man. Stem Cells 1999;17:203-9.
84. Dower WJ, Cwirla SE, Balasubramanian P, Schatz PJ, Baccanari DP, Barrett RW. Peptide agonists of the thrombopoietin receptor. Stem Cells 1998;16(Suppl 2):21-9.
85. Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 2004;25:52-60.
86. Gibson BE, Todd A, Roberts I, Pamphilon D, Rodeck C, Bolton-Maggs P, et al. Transfusion guidelines for neonates and older children. Br J Haematol 2004;124:433-53.